Trending NewsTrending NewsNASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $14.81 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$15.24 +0.43 (+2.93%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cullinan Therapeutics Stock (NASDAQ:CGEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$14.67▼$15.6250-Day Range$14.81▼$22.9552-Week Range$5.68▼$23.19Volume1.72 million shsAverage Volume1.16 million shsMarket Capitalization$953.17 millionP/E RatioN/ADividend YieldN/APrice Target$33.71Consensus RatingModerate Buy Company Overview Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need. Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations. Cullinan has also advanced additional investigational programs designed to target cancer-related pathways and immune mechanisms, including antibody-based therapies and other precision-medicine approaches. The company was founded as Cullinan Oncology and changed its name to Cullinan Therapeutics in 2024. It is headquartered in San Francisco, California, and its activities are primarily focused on the research and clinical development of medicines for patients in the United States and international markets. Cullinan is led by Chief Executive Officer Nadim Ahmed.AI Generated. May Contain Errors. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCGEM MarketRank™: Cullinan Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 235th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCullinan Therapeutics has a consensus price target of $33.71, representing about 127.6% upside from its current price of $14.81.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cullinan Therapeutics are expected to grow in the coming year, from ($3.08) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.37% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 10.88, which indicates bearish sentiment.Change versus previous monthShort interest in Cullinan Therapeutics has recently decreased by 7.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentCullinan Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Cullinan Therapeutics this week, compared to 5 articles on an average week.Search Interest2 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $922,920.00 in company stock.Percentage Held by Insiders8.60% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Stock News HeadlinesCullinan Therapeutics (NASDAQ:CGEM) Earns Buy Rating from BTIG ResearchSeptember 27 at 1:24 AM | americanbankingnews.comCullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026September 26 at 7:21 PM | finance.yahoo.comThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents. | Brownstone Research (Ad)Cullinan drops after delaying early-stage trial data for arthritis therapySeptember 24, 2026 | seekingalpha.comCullinan Therapeutics plans Q4 2026 clinical data updates across three T cell engager programsSeptember 24, 2026 | msn.comCGEM stock extends losses after Cullinan delays arthritis update to December — zipalertinib safety worries lingerSeptember 24, 2026 | msn.comCullinan Therapeutics Outlines Q4 Milestones For T Cell Engager PipelineSeptember 24, 2026 | rttnews.comInsider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $172,560.00 in StockSeptember 11, 2026 | insidertrades.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $10.35 at the start of the year. Since then, CGEM shares have increased by 43.1% and is now trading at $14.81. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.01. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $232 million in an initial public offering on Friday, January 8th 2021. The company issued 11,900,000 shares at a price of $19.00-$20.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Cullinan Therapeutics' top institutional investors include BlackRock Inc. (8.51%), Blue Owl Capital Holdings LP (2.39%), Boone Capital Management LLC (1.09%) and Elmind Capital LP (1.07%). Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Corrine Savill, Jeffrey Alan Jones, Jennifer Michaelson, Jacquelyn L Sumer, Mary Kay Fenton and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings8/06/2026Today9/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 4 days ago, CGEM's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinantherapeutics.com Phone617-410-4650FaxN/AEmployees109Year Founded2016Price Target and Rating Average Price Target for Cullinan Therapeutics$33.71 High Price Target$42.00 Low Price Target$26.00 Potential Upside/Downside+127.6%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$219.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.89% Return on Assets-48.18% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book2.14Miscellaneous Outstanding Shares64,360,000Free Float58,820,000Market Cap$953.17 million OptionableOptionable Beta0.02 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CGEM) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
